Yashoda Hospitals joins Natco for clinical trials of Molnupiravir for Covid patients

Pre-clinical (animal) studies have found that Molnupiravir has remarkably reduced SARS-CoV-2 load and was found to have completely suppressed the spread of disease from animal to animal, and the virus multiplication development had stopped.

Leave a Reply

Your email address will not be published. Required fields are marked *